strong pave way
jakafi beat vs con management increas sale
guidanc management note jakafi uptak gvhd
progress well believ increas investor focu
gvhd readout itacitinib expect
jakafi perform drive result jakafi sale quarter
consensu expect management note jakafi
y/i sale growth driven primarili demand minim
impact inventori management note jakafi current use elig
mf patient elig pv patient total patient
therapi increas y/i mf y/i pv specif
provid jakafi uptak steroid-refractori acut gvhd management note
launch perform exceed compani intern expect
jakafi gvhd like surpass total sale includ
spontan post-approv use management previous guid base
jakafi recent perform management revis jakafi sale guidanc
upward reiter long-term peak
sale guidanc oper expens
consensu expect management reiter prior guidanc non-gaap
 non-gaap sg
addit takeaway call nda fgfr inhibitor pemigatinib
cholangiocarcinoma cca submit fda pivot data
submiss recent highlight esmo see earlier note
data pemigatinib bladder cancer expect mid-lat
phiii data ruxolitinib cream atop dermat track phiii
data vitiligo expect management note busi develop
focu remain primarili hematology/oncolog asset could help diversifi
compani revenu base recal jakafi face
patent expir management also open evalu extern mf/pv asset
build jakafi mpn franchis dermatolog immunolog asset
management note observ impact yet jakafi recent
launch mf therapi inreb fedratinib management believ drug price
strategi market materi suggest inreb posit
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
second-lin therapi jakafi life cycl extens program management note
bioequivalence/bioavail work extended-releas formul
current underway complet regulatori discuss
like combin data jakafi jakafi pim jakafi
itacitinib avail
focu turn gvhd data believ beat
increas jakafi sale guidanc like increas investor confid
durabl jakafi franchis drug abil approach
upper end possibl stretch past management long-term peak sale guidanc
beyond jakafi believ investor find management commentari
regard busi develop construct address potenti
jakafi cliff mid-lat next key catalyst remain
readout itacitinib acut gvhd would expect greater
investor focu given posit commentari jakafi earli uptak gvhd
drug first full quarter set also await detail data
studi jakafi gvhd particularli key secondari endpoint
recal posit top line data recent report see note
believ detail data could present
jakafi perform oncolog dermatolog pipelin readout drive
jakafi perform oncolog dermatolog pipelin readout drive
deriv price target discount cash flow analysi
factor explicit revenu project use
discount rate termin growth rate
jakafi sale upper rang long-term guidanc clear blockbust
perform key late-stag pipelin asset strong contribut
early-stag pipelin jakafi sale peak total revenu
itacitinib first-lin gvhd gener peak sale ruxolitinib
cream gener peak sale across vitiligo atop
dermat early-stag pipelin contribut aggreg peak sale
jakafi sale midpoint long-term guidanc coupl strong
pipelin realiz jakafi sale manag long-term
guidanc peak total revenu approv
strong uptak late-stag pipelin asset itacitinib first-lin gvhd peak
sale ruxolitinib cream vitiligo atop dermat
aggreg peak sale aggreg peak sale
early-stag pipelin
jakafi sale manag guidanc modest royalti revenu
minim pipelin success jakafi sale peak royalti revenu
jakafi ex-u olumi peak iclusig sale
aggreg peak pipelin revenu
jakafi base busi room
grow hold right jakafi
ruxolitinib ex-u right held
novarti jakafi sale
grown y/i
y/i forecast
continu growth jakafi
meaning contribut label
expans graft versu host diseas
gvhd forecast peak jakafi sale
roughli midpoint
manag long-term guidanc
prior jakafi patent expir
pipelin effort come focu
late throughout
develop broad multi-asset pipelin
believ key area investor focu
phiii asset itacitinib gvhd
ruxolitinib cream vitiligo atop
effort fgfr inhibitor pemigatinib
first phiii readout itacitinib first-lin
gvhd expect first set
phiii ruxolitinib cream data expect
adjust sale itactinib
gvhd ruxolitinib cream
jakafi life cycl extens effort
pemigatinib bladder cancer also
expect
factor grow jakafi sale base
strong contribut late-stag
pipelin result find current
risk/reward valuat balanc
phiii data jakafi itacitinib gvhd
phiii data ruxolitinib cream atop
data pemigatinib bladder cancer
tumor agnost program
addit detail jakafi life cycl
phiii data itacitinib steroid-na acut
gvhd studi
phiii data ruxolitinib cream atop
dermat
phiii data jakafi steroid-refractori
chronic gvhd studi
phii data inhibitor parsaclisib
phii data antibodi
updat jakafi life cycl extens
program
risk achiev price
 jakafi sale perform
poor phiii result itacitinib and/or
ruxolitinib cream either due outright safeti
and/or efficaci failur due result
clinic meaning
failur and/or minim success early-
stage pipelin asset
mileston contract revenu
cost expens
product revenu incl definite-liv intang amort
chang fair valu acquisition-rel conting consider
total cost expens
incom loss oper
unreal loss long-term invest
expens relat senior note convers
incom loss provis incom tax
provis incom tax
cash equival
prepaid expens current asset
restrict cash invest
properti equip net
accru current liabil
accumul comprehens incom
total liabil stockhold equiti
flow oper activ
in-process research develop
expens relat senior note convers
unreal loss long-term invest
chang fair valu acquisition-rel conting consider
chang oper asset liabil
prepaid expens asset
accru liabil
net cash provid use oper activ
flow invest activ
acquisit busi net cash acquir
purchas long-term invest
purchas market secur
sale matur market secur
net cash use invest activ
flow financ activ
proce issuanc common stock stock plan
proce issuanc common stock net
paid connect senior note convers
payment conting consider
net cash provid financ activ
effect exchang rate cash cash equival restrict cash invest
net increas cash cash equival restrict cash invest
cash equival restrict cash invest begin period
cash equival restrict cash invest end period
